Feraheme

ApprovedSmall molecule

SStanford University

Feraheme is one of 238 small molecule programs targeting Stroke. It is currently in Approved.

Indications

Total Trials

Active Trials

237

Competitors

Pipeline

Status by Indication[3][1]

Indication

StrokeActive, not recruiting

Kidney TransplantActive, not recruiting

AnemiaActive, not recruiting

OsteomyelitisActive, not recruiting

Multiple SclerosisActive, not recruiting

MigraineActive, not recruiting

Glioblastoma MultiformeActive, not recruiting

StrokeApproved

Active, not recruiting

Kidney TransplantPreclinical

Active, not recruiting

AnemiaPhase 1/Phase 2

Active, not recruiting

OsteomyelitisPhase 2

Active, not recruiting

Multiple SclerosisPreclinical

Active, not recruiting

MigrainePreclinical

Active, not recruiting

Glioblastoma MultiformePhase 1

Active, not recruiting

Competition

Competitive Landscape

560 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

Feraheme

SStanford University

Approved

1 2

Betaseron

Bayer

Preclinical

16 3

Tysabri

Biogen

Preclinical

14 4

Avonex

EMD Serono

Preclinical

22 5

Campath

GGenzyme, a Sanofi Company

Preclinical

12 6

Zinbryta

Roche

Preclinical

2 7

Flomax

Sanofi

Preclinical

1 8

Pred Forte

Myfortic

Novantrone

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Nanoparticle1 trial

Clinical and Technical Feasibility of a Ultrasuperparamagnetic Nanoparticle Iron Oxide (USPIO)-Enhanced Magnetic Resonance Lymph Node Imaging

Completed·MM.D. Anderson Cancer Center·N/A·NCT01815333·10 enrolled

Anemia1 trial

Active Preoperative Anemia Management in Patients Undergoing Cardiac Surgery

Terminated·UUniversity of Texas Southwestern Medical Center·Phase 1/2·NCT02189889·5 enrolled

Migraine1 trial

Investigation of Vascular Inflammation in Migraine Using Molecular Nano-imaging and Black Blood Imaging MRI

Completed·DDanish Headache Center·N/A·NCT02549898·34 enrolled

Osteomyelitis1 trial

Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI

Completed·HHeike E Daldrup-Link·Phase 2·NCT01336803·32 enrolled

Glioblastoma Multiforme1 trial

qBOLD MRI of Glioblastoma Multiforme for Assessment of Tumor Hypoxia.

Completed·SSunnybrook Health Sciences Centre·Phase 1·NCT02466828·10 enrolled

3 more indications

Multiple Sclerosis1 trial

High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases

Withdrawn·SStanford University··NCT01973517

Stroke1 trial

Predicting Stroke Risk in ICAD With Novel MRI

Recruiting·NNorthwestern University·Phase 4·NCT05515874·100 enrolled

Kidney Transplant1 trial

Imaging Kidney Transplant Rejection Using Ferumoxytol-Enhanced Magnetic Resonance

Completed·SStanford University·N/A·NCT02006108·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Feraheme. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Feraheme compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Feraheme. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Stanford University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SStanford University

Feraheme

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Nanoparticle1 trial

Anemia1 trial

Migraine1 trial

Osteomyelitis1 trial

Glioblastoma Multiforme1 trial

Multiple Sclerosis1 trial

Stroke1 trial

Kidney Transplant1 trial

References

Drug Info

Quick Facts

Related News